{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:19:24Z","timestamp":1784697564649,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,2,6]],"date-time":"2015-02-06T00:00:00Z","timestamp":1423180800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s40261-015-0268-8","type":"journal-article","created":{"date-parts":[[2015,2,5]],"date-time":"2015-02-05T03:58:26Z","timestamp":1423108706000},"page":"169-177","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and Safety of Sublingual Fentanyl Tablets for the Management of Breakthrough Pain in Patients with Chronic Musculoskeletal Pain with Neuropathic Component: Multicenter Prospective Study"],"prefix":"10.1007","volume":"35","author":[{"given":"Luz","family":"C\u00e1novas-Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 J.","family":"Carceller-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"D\u00edaz-Parada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Illodo-Miramontes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Freire-Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"De la Iglesia-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n Garc\u00eda","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"L\u00f3pez-Ulloa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Dom\u00ednguez-Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Camba-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,6]]},"reference":[{"key":"268_CR1","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1212\/01.wnl.0000282763.29778.59","volume":"70","author":"RD Treede","year":"2008","unstructured":"Treede RD, Jensen TS, Campbell JN, et al. Redefinition of neuropathic pain and a grading system for clinical use: consensus statement on clinical and research diagnostic criteria. Neurology. 2008;70:1630\u20135.","journal-title":"Neurology."},{"key":"268_CR2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/01.ajp.0000210945.27052.b3","volume":"23","author":"CE Argoff","year":"2007","unstructured":"Argoff CE. The coexistence of neuropathic pain, sleep and psychiatric disorder: a novel treatment approach. Clin J Pain. 2007;23:15\u201322.","journal-title":"Clin J Pain."},{"key":"268_CR3","first-page":"S263","volume":"12","author":"BH McCarberg","year":"2006","unstructured":"McCarberg BH, Billington R. Consequences of neuropathic pain: quality of life issues and associated costs. Am J Managed Care. 2006;12:S263\u20138.","journal-title":"Am J Managed Care."},{"key":"268_CR4","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMe030014","volume":"348","author":"KM Foley","year":"2003","unstructured":"Foley KM. Opioids and chronic neuropathic pain. N Engl J Med. 2003;348:1279\u201381.","journal-title":"N Engl J Med."},{"key":"268_CR5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jpain.2008.10.008","volume":"10","author":"R Chou","year":"2009","unstructured":"Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113\u201330.","journal-title":"J Pain."},{"key":"268_CR6","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.pain.2004.09.019","volume":"112","author":"E Kalso","year":"2004","unstructured":"Kalso E, Edwards JE, Moore RA, et al. Opioids in chronic non-cancer pain: systematic review on efficacy and safety. Pain. 2004;112:372\u201380.","journal-title":"Pain."},{"key":"268_CR7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0304-3959(90)90004-W","volume":"41","author":"RK Portenoy","year":"1990","unstructured":"Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41:273\u201381.","journal-title":"Pain."},{"key":"268_CR8","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jpain.2006.02.003","volume":"7","author":"RK Portenoy","year":"2006","unstructured":"Portenoy RK, Bennett DS, Rauck R, et al. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J Pain. 2006;7:583\u201391.","journal-title":"J Pain."},{"key":"268_CR9","first-page":"CD004311","volume":"10","author":"G Zeppetella","year":"2013","unstructured":"Zeppetella G, Davies AN. Opioids for the management of breakthrough pain in cancer patients. Cochrane Database Syst Rev. 2013;10:CD004311.","journal-title":"Cochrane Database Syst Rev"},{"key":"268_CR10","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.clinthera.2007.04.007","volume":"29","author":"DV Simpson","year":"2007","unstructured":"Simpson DV, Messina J, Xie F, et al. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain. A multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29:588\u2013601.","journal-title":"Clin Ther."},{"key":"268_CR11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pain.2004.09.012","volume":"113","author":"RH Dworkin","year":"2005","unstructured":"Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113:9\u201319.","journal-title":"Pain"},{"key":"268_CR12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/bja\/aet126","volume":"111","author":"RA Moore","year":"2013","unstructured":"Moore RA, Derry S, Wiffen PJ. Challenges in design and interpretation of chronic pain trials. Br J Anaesth. 2013;111:38\u201345.","journal-title":"Br J Anaesth."},{"key":"268_CR13","unstructured":"European Medicines Agency. Guideline for good clinical practice: ICH Topic E6 (R1). Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002874.pdf . Accessed 7 May 2014."},{"key":"268_CR14","unstructured":"Abstral (Sublingual Fentanyl Citrate). Summary of product characteristics. Available at: http:\/\/www.abstral.co.uk\/downloads\/Abstral_SPC.pdf . Accessed 7 May 2014."},{"key":"268_CR15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1477-7525-5-66","volume":"5","author":"C Perez","year":"2007","unstructured":"Perez C, Galvez R, Huelbes S, et al. Validity and reliability of the Spanish version of the DN4 (Douleur neuropathique 4 questions) questionnaire for differential diagnosis of pain syndromes associated to a neuropathic or somatic component. Health Qual Life Outcomes. 2007;5:66.","journal-title":"Health Qual Life Outcomes."},{"key":"268_CR16","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group. EuroQol a new facility for the measurement of health related quality of life. Health Policy. 1990;16:199\u2013208.","journal-title":"Health Policy."},{"key":"268_CR17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0025-7753(03)73601-X","volume":"120","author":"X Badia","year":"2003","unstructured":"Badia X, Muriel C, Gracia A, et al. Validation of Brief Pain Inventory in patients with oncological pain [in Spanish]. Med Clin (Barc). 2003;120:52\u20139.","journal-title":"Med Clin (Barc)."},{"key":"268_CR18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1360-0443.1994.tb03332.x","volume":"89","author":"D Raistrick","year":"1994","unstructured":"Raistrick D, Bradshaw J, Tober G, et al. Development of the Leeds Dependence Questionnaire (LDQ): a questionnaire to measure alcohol and opiate dependence in the context of a treatment evaluation package. Addiction. 1994;89:563\u201372.","journal-title":"Addiction."},{"key":"268_CR19","unstructured":"Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville: US Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse and Mental Health Administration; 1976. p. 217\u201322. (313\u201331)."},{"key":"268_CR20","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/MJT.0b013e3181671c5a","volume":"15","author":"WA Katz","year":"2008","unstructured":"Katz WA, Barkin RL. Dilemmas in chronic\/persistent pain management. Am J Ther. 2008;15:256\u201364.","journal-title":"Am J Ther."},{"key":"268_CR21","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.pain.2004.03.006","volume":"109","author":"MA Caudill-Slosberg","year":"2004","unstructured":"Caudill-Slosberg MA, Schwartz LM, Woloshin S. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000. Pain. 2004;109:514\u20139.","journal-title":"Pain"},{"key":"268_CR22","first-page":"CD004959","volume":"8","author":"LE Chaparro","year":"2013","unstructured":"Chaparro LE, Furlan AD, Deshpande A, et al. Opioids compared to placebo or other treatments for chronic low-back pain. Cochrane Database Syst Rev. 2013;8:CD004959.","journal-title":"Cochrane Database Syst Rev"},{"key":"268_CR23","first-page":"CD006146","volume":"8","author":"ED McNicol","year":"2013","unstructured":"McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2013;8:CD006146.","journal-title":"Cochrane Database Syst Rev"},{"key":"268_CR24","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1177\/0269216309356138","volume":"24","author":"B Lennernas","year":"2010","unstructured":"Lennernas B, Frank-Lissbrant I, Lennernas H, et al. Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study. Palliat Med. 2010;24:286\u201393.","journal-title":"Palliat Med."},{"key":"268_CR25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jpain.2008.10.007","volume":"10","author":"R Chou","year":"2009","unstructured":"Chou R, Ballantyne JC, Fanciullo GJ, et al. Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10:147\u201359.","journal-title":"J Pain."},{"key":"268_CR26","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1185\/03007990903368310","volume":"25","author":"RL Rauck","year":"2009","unstructured":"Rauck RL, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin. 2009;25:2877\u201385.","journal-title":"Curr Med Res Opin."},{"key":"268_CR27","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1185\/03007995.2010.545380","volume":"27","author":"S Nalamachu","year":"2011","unstructured":"Nalamachu S, Hassman D, Wallace MS, et al. Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain. Curr Med Res Opin. 2011;27:519\u201330.","journal-title":"Curr Med Res Opin."},{"key":"268_CR28","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40261-013-0111-z","volume":"33","author":"J Guitart","year":"2013","unstructured":"Guitart J, Vargas I, De Sanctis V, et al. Efficacy and safety of sublingual fentanyl orally disintegrating tablets in patients with breakthrough pain: multicentre prospective study. Clin Drug Invest. 2013;33:675\u201383.","journal-title":"Clin Drug Invest."},{"key":"268_CR29","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0304-3959(00)00339-0","volume":"88","author":"JT Farrar","year":"2000","unstructured":"Farrar JT, Portenoy RK, Berlin JA, et al. Defining the clinically important difference in pain outcome measures. Pain. 2000;88:287\u201394.","journal-title":"Pain."},{"key":"268_CR30","doi-asserted-by":"crossref","first-page":"297","DOI":"10.5055\/jom.2011.0071","volume":"7","author":"LR Webster","year":"2011","unstructured":"Webster LR, Messina J, Xie F, et al. Effect of fentanyl buccal tablet on pain-related anxiety: a 4-week open-label study among opioid-tolerant patients with chronic and breakthrough pain. J Opioid Manag. 2011;7:297\u2013308.","journal-title":"J Opioid Manag."},{"key":"268_CR31","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1185\/03007995.2011.583231","volume":"27","author":"MA \u00dcberall","year":"2011","unstructured":"\u00dcberall MA, Muller-Schwefe GH. Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain. Curr Med Res Opin. 2011;27:1385\u201394.","journal-title":"Curr Med Res Opin."},{"key":"268_CR32","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1526-4637.2007.00370.x","volume":"9","author":"DA Fishbain","year":"2008","unstructured":"Fishbain DA, Cole B, Lewis J, et al. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develops abuse\/addiction and\/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med. 2008;9:444\u201359.","journal-title":"Pain Med."},{"key":"268_CR33","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jpainsymman.2010.03.012","volume":"41","author":"SD Passik","year":"2011","unstructured":"Passik SD, Messina J, Golsorkhi A, et al. Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain. J Pain Symptom Manag. 2011;41:116\u201325.","journal-title":"J Pain Symptom Manag."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-015-0268-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-015-0268-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-015-0268-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:28:54Z","timestamp":1559489334000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-015-0268-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,6]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["268"],"URL":"https:\/\/doi.org\/10.1007\/s40261-015-0268-8","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,6]]}}}